Jonathan D. Cheng
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Otorhinolaryngology top 0.2%
- Head and Neck Cancer Studies
Papers in
-
- Head and Neck Cancer Studies 22
- Oncology 78
- Cancer Immunotherapy and Biomarkers 42
- Peptidase Inhibition and Analysis 28
- Co-authors
- Tanguy Y. SeiwertJared LuncefordTerrill K. McClanahanLaura Q.M. ChowRaanan BergerErin MurphyLouis M. WeinerJennifer H. Yearley
- Journals
- Journal of Clinical Oncology (37 papers)Cancer Research (6 papers)Clinical Cancer Research (5 papers)Journal of Medicinal Chemistry (3 papers)International Journal of Radiation Oncology*Biology*Physics (3 papers)
- Partner nations
- United StatesSouth KoreaJapan
In The Last Decade
Jonathan D. Cheng
111 papers receiving 11.9k citations
Hit Papers
Peers
Comparison fields: 5 of 133
- Oncology 8.8k
- Otorhinolaryngology 1.4k
- Cancer Research 2.2k
- Immunology 3.0k
- Pulmonary and Respiratory Medicine 3.3k
Countries citing papers authored by Jonathan D. Cheng
This map shows the geographic impact of Jonathan D. Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan D. Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan D. Cheng more than expected).
Fields of papers citing papers by Jonathan D. Cheng
This network shows the impact of papers produced by Jonathan D. Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan D. Cheng. The network helps show where Jonathan D. Cheng may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jonathan D. Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 3 | |
| 2 | 2022 | 54 | |
| 3 | 2021 | 0 | |
| 4 | 2020 | 83 | |
| 5 | 2019 | 148 | |
| 6 | 2018 | 27 | |
| 7 | PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer Hit paper breakdown → | 2017 | 453 |
| 8 | Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study Hit paper breakdown → | 2017 | 497 |
| 9 | Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial Hit paper breakdown → | 2016 | 1275 |
| 10 | 2015 | 82 | |
| 11 | 2015 | 27 | |
| 12 | 2014 | 25 | |
| 13 | 2012 | 47 | |
| 14 | 2011 | 28 | |
| 15 | 2011 | 243 | |
| 16 | 2007 | 7 | |
| 17 | Inhibitors of the stromal protease fibroblast activation protein attenuate tumor growth in vivo | 2006 | 3 |
| 18 | 2006 | 157 | |
| 19 | Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647, 2003. | 2003 | 62 |
| 20 | Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. | 2002 | 198 |
About Jonathan D. Cheng
Jonathan D. Cheng is a scholar working on Otorhinolaryngology, Oncology, Cancer Research, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 113 papers that have together received 12.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (42 papers), Peptidase Inhibition and Analysis (28 papers), Head and Neck Cancer Studies (22 papers), Lung Cancer Treatments and Mutations (15 papers), Esophageal Cancer Research and Treatment (12 papers), Cancer Genomics and Diagnostics (11 papers), Neuropeptides and Animal Physiology (11 papers) and Protease and Inhibitor Mechanisms (10 papers). The work is most often cited by research in Oncology (8.8k citations), Otorhinolaryngology (1.4k citations), Cancer Research (2.2k citations), Immunology (3.0k citations) and Pulmonary and Respiratory Medicine (3.3k citations). Jonathan D. Cheng has collaborated with scholars based in United States, South Korea and Japan. Frequent co-authors include Tanguy Y. Seiwert, Jared Lunceford, Terrill K. McClanahan, Laura Q.M. Chow, Raanan Berger, Erin Murphy, Louis M. Weiner, Jennifer H. Yearley, Sarina A. Piha‐Paul and Mark Ayers. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Journal of Medicinal Chemistry and International Journal of Radiation Oncology*Biology*Physics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.